FDA Approves Inovio's INO-3107, Its First Commercial Product
INO has more than doubled off its 52-week low of $0.563 on elevated volume (5.4× avg).
Summary
The FDA approved Inovio's INO-3107 for a rare respiratory condition, the company's first-ever approved product. This was the binary event the stock has been trading on — the Q2 10-Q flagged the FDA decision as due October 30, 2026, and the company carried a going concern warning with cash runway only into late Q1 2027. An approval converts Inovio from a clinical-stage story into a commercial one and opens the door to revenue, partnership, or financing options that were not available before. The company also holds an $80.4M judgment against VGXI and GeneOne won in Pennsylvania state court on October 20, which adds to the balance-sheet picture.
At the time of this announcement, INO was trading at $1.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.3M. The 52-week trading range was $0.56 to $2.72. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.